ADRESTIA
LIVE

Serial Number

79307379

Owner

Adrestia Therapeutics Ltd

Attorney

Ben Natter

Filing Date

Dec 8, 2020

Add to watchlist:

No watchlists yet
View on USPTO

ADRESTIA Trademark

Serial Number: 79307379 • Registration: 6709002

ADRESTIA is a trademark filed by Adrestia Therapeutics Ltd on December 8, 2020. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Adrestia Therapeutics Ltd

Moneta Building,

Entity Type: 99

Trademark Details

Filing Date

December 8, 2020

Registration Date

April 26, 2022

Published for Opposition

February 8, 2022

Goods & Services

Medical and veterinary preparations for the treatment of immune response disorders, cardiovascular diseases, genetic conditions, cancer, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases and infectious diseases in humans and animals; pharmaceutical substances and preparations for human use for the diagnosis and treatment of immune response disorders, cardiovascular diseases, genetic conditions, cancer, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases and infectious diseases; biopharmaceutical substances and preparations for human use for use in the diagnosis and treatment of immune response disorders, cardiovascular diseases, genetic conditions, cancer, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases and infectious diseases; reagents, diagnostic preparations and therapeutic preparations in the nature of biological, biochemical and chemical reagents and vaccines for medical purposes; biological preparations for medical purposes, for the diagnosis and treatment of immune response disorders, cardiovascular diseases, genetic conditions, cancer, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases and infectious diseases; medical preparations for use in gene therapy; diagnostic preparations for medical purposes; therapeutic and diagnostic preparations, namely, small molecules for medical use

Chemicals used in science; biological preparations for use in science; biochemicals for research use; cell lines and bio-production cell lines for scientific, laboratory or medical research; reagents, plasmids and assays for scientific, genetic and medical research; molecular biology research tools, in the nature of biological and biochemical reagents; biological and chemical reagents for research use; chemical reagents for scientific and research purposes; proteins in raw material form for scientific and medical research; gene extracts for research purposes; chemicals and biochemicals for drug discovery, lead identification, diagnostics, profiling and research

Medical services; medical and pharmaceutical advisory and consultancy services; preparing pharmaceuticals, namely pharmaceutical compounding services for others; providing personalised medicine services and personalised medical diagnostic reporting services; providing personal medical information; provision of medical information; provision of information to enable human diagnosis of medical conditions; providing medical information to enable healthcare professionals to enable the monitoring of patients; providing medical information to healthcare professionals to enable the assessment of progress in disease and treatment; consultancy and advisory relating to all the aforesaid services

Medical, scientific and industrial research services in the field of cells, cell therapies, genome editing, genetic engineering and gene therapies and targeting therapies to individuals; pharmaceutical and biopharmaceutical research and development services; medical and pharmacological research services; examination and testing of genes for scientific research purposes; development, examination and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; development, examination and testing of medicaments products; development of test systems for pharmaceutical and biopharmaceutical products; development of databases in the medical, pharmaceutical and biopharmaceutical field; development of gene databases; research and development services in the creation of databases and collections of information on biologicals, genetic material, genetic information, chemicals and compounds for research purposes; providing biological and medical research information; providing scientific research information and data in relation to health and disease state; medical research into personalised medicine; medical research services in the field of personalised diagnostics, medical research services in the field of personal medical profiles; provision of scientific research information in the field of personalised medicine; pharmaceutical drug development services; consultancy and advisory relating to all the aforesaid services

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Sep 26, 2022 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Sep 2, 2022 FICS
FINAL DISPOSITION PROCESSED
Sep 2, 2022 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jul 26, 2022 FICR
CHANGE OF NAME/ADDRESS REC'D FROM IB
May 27, 2022 ADCH
REGISTERED-PRINCIPAL REGISTER
Apr 26, 2022 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 8, 2022 NPUB
PUBLISHED FOR OPPOSITION
Feb 8, 2022 PUBO
NOTIFICATION PROCESSED BY IB
Feb 6, 2022 GPNX
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jan 20, 2022 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jan 20, 2022 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jan 20, 2022 REAP
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jan 19, 2022 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Jan 19, 2022 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 19, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 3, 2022 CNSA
EXAMINER'S AMENDMENT ENTERED
Dec 23, 2021 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Dec 23, 2021 GNEN
EXAMINERS AMENDMENT E-MAILED
Dec 23, 2021 GNEA
EXAMINERS AMENDMENT -WRITTEN
Dec 23, 2021 CNEA
NOTIFICATION OF FINAL REFUSAL EMAILED
Dec 22, 2021 GNFN
FINAL REFUSAL E-MAILED
Dec 22, 2021 GNFR
FINAL REFUSAL WRITTEN
Dec 22, 2021 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 14, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 14, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 14, 2021 TROA
REFUSAL PROCESSED BY IB
Jul 11, 2021 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jun 21, 2021 RFCS
REFUSAL PROCESSED BY MPU
Jun 21, 2021 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jun 12, 2021 RFCR
NON-FINAL ACTION WRITTEN
Jun 11, 2021 CNRT
NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
Jun 7, 2021 RFWR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
May 29, 2021 RFCR
NON-FINAL ACTION WRITTEN
May 28, 2021 CNRT
ASSIGNED TO EXAMINER
May 28, 2021 DOCK
APPLICATION FILING RECEIPT MAILED
Mar 30, 2021 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 26, 2021 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Mar 25, 2021 REPR